ZYZ-488 is a competitive apoptotic protease activating factor-1 (Apaf-1) inhibitor. ZYZ-488 inhibits the activation of binding protein procaspase-9 and procaspase-3 In Vitro ZYZ-488 decreases apoptosis in hypoxic H9c2 cells. ZYZ-488 inhibits hypoxia induced Apaf-1-mediated activation of procaspase-9 and procaspase-3. ZYZ-488 decreases myocardial enzyme release, inhibits cardiomyocyte apoptosis, and suppresses the activation of the downstream cascade of caspases. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ZYZ-488 (33.9-67.8 mg/kg; intramuscularly; for 3 days) protected against myocardial apoptosis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6 mice (8-10 weeks old)Dosage: myocardial infarction + ZYZ-488 (33.9 mg/kg);\nmyocardial infraction + ZYZ-488 (67.8 mg/kg); Administration: Intramuscularly; for 3 days Result: Inhibited Apaf-1-mediated activation of procaspase-9 and procaspase-3. Form:Solid IC50& Target:Apoptotic protease activating factor-1